1 citations,
April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences” The mouse models are effective for testing new hair loss treatments.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
2 citations,
September 2022 in “American Journal of Clinical Dermatology” 23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
1 citations,
January 2022 in “Journal of Biosciences and Medicines” Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
January 2024 in “JEADV clinical practice” Patients were highly satisfied with shared medical appointments for hair loss treatment.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.